# A Study to Assess the Efficacy and Safety of Ipragliflozin in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin

> **NCT02794792** · PHASE3 · COMPLETED · sponsor: **Astellas Pharma Europe B.V.** · enrollment: 268 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Ipragliflozin L-proline
- **DRUG:** Metformin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02794792
- **Lead sponsor:** Astellas Pharma Europe B.V.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-05-11
- **Primary completion:** 2017-03-02
- **Final completion:** 2017-06-20
- **Target enrollment:** 268 (ACTUAL)
- **Last updated:** 2024-11-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02794792

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02794792, "A Study to Assess the Efficacy and Safety of Ipragliflozin in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT02794792. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*